Charles River Laboratories International (NYSE:CRL) Issues FY 2026 Earnings Guidance

Charles River Laboratories International (NYSE:CRL) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 10.700-11.200 for the period, compared to the consensus earnings per share estimate of 10.770. The company issued revenue guidance of -, compared to the consensus revenue estimate of $4.1 billion.

Charles River Laboratories International Stock Performance

CRL stock traded down $0.66 during midday trading on Thursday, reaching $157.34. 276,359 shares of the company’s stock traded hands, compared to its average volume of 932,376. The company has a current ratio of 1.37, a quick ratio of 1.10 and a debt-to-equity ratio of 0.64. Charles River Laboratories International has a 52-week low of $91.86 and a 52-week high of $228.88. The stock has a market cap of $7.74 billion, a P/E ratio of -100.87, a PEG ratio of 4.80 and a beta of 1.63. The stock’s 50-day moving average is $201.46 and its 200 day moving average is $179.44.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, February 18th. The medical research company reported $2.39 earnings per share for the quarter, beating the consensus estimate of $2.33 by $0.06. The company had revenue of $994.23 million for the quarter, compared to the consensus estimate of $986.98 million. Charles River Laboratories International had a positive return on equity of 15.78% and a negative net margin of 2.07%.Charles River Laboratories International’s quarterly revenue was down .8% compared to the same quarter last year. During the same period in the previous year, the business earned $2.66 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. As a group, analysts anticipate that Charles River Laboratories International will post 9.36 EPS for the current year.

Analyst Ratings Changes

CRL has been the topic of several recent research reports. TD Cowen reissued a “buy” rating on shares of Charles River Laboratories International in a research report on Thursday, January 22nd. JPMorgan Chase & Co. boosted their price objective on shares of Charles River Laboratories International from $165.00 to $190.00 and gave the company a “neutral” rating in a research report on Monday, December 15th. Weiss Ratings reissued a “sell (d)” rating on shares of Charles River Laboratories International in a research note on Wednesday, January 21st. Argus set a $200.00 target price on shares of Charles River Laboratories International in a report on Monday, November 17th. Finally, Morgan Stanley set a $185.00 price target on shares of Charles River Laboratories International in a report on Monday, December 1st. Ten equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $208.31.

Key Stories Impacting Charles River Laboratories International

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Q4 headline beat — CRL reported EPS of $2.39 and revenue of $994.2M, topping consensus and showing margin expansion, which is supportive of near‑term earnings credibility. Charles River Laboratories (CRL) Q4 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Upbeat FY‑2026 profit outlook — management reiterated a stronger profit outlook driven by recovering demand for drug‑development services, which supports medium‑term revenue recovery assumptions. Charles River forecasts upbeat 2026 profit on improved demand for drug development services
• Positive Sentiment: Management expects EPS growth from new leadership, M&A and cost savings — company projects up to ~9% EPS growth driven by acquisitions and margin initiatives, a constructive catalyst if execution continues. Charles River projects up to 9% EPS growth in 2026 as new CEO, acquisitions, and cost savings drive margin expansion
• Neutral Sentiment: Executive appointments announced — leadership changes can be neutral near‑term but important for execution of the margin and M&A plan. Charles River Laboratories Announces Executive Appointments
• Neutral Sentiment: FY‑2026 guidance is essentially in line with Street estimates (10.70–11.20 vs ~10.77 consensus), so the guide removed some downside but didn’t materially surprise on the upside. Press Release / Slide Deck
• Negative Sentiment: Organic growth weakness — analysts flagged declines in organic growth across all segments, a core investor concern that explains downward pressure despite the beats. CRL Stock Down Despite Q4 Earnings & Revenue Beat, Margins Rise
• Negative Sentiment: Mixed/erroneous reporting created volatility — at least one circulated transcript reported a wildly negative EPS figure, which likely added short‑term confusion and selling pressure. Charles River Laboratories International, Inc. Q4 2025 Earnings Call Transcript

Institutional Investors Weigh In On Charles River Laboratories International

Several institutional investors have recently added to or reduced their stakes in CRL. State Street Corp increased its holdings in Charles River Laboratories International by 2.2% in the fourth quarter. State Street Corp now owns 1,871,688 shares of the medical research company’s stock valued at $373,364,000 after buying an additional 40,535 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Charles River Laboratories International by 27.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,442,224 shares of the medical research company’s stock valued at $287,703,000 after acquiring an additional 311,319 shares during the period. Invesco Ltd. grew its position in shares of Charles River Laboratories International by 1.0% during the 3rd quarter. Invesco Ltd. now owns 1,249,178 shares of the medical research company’s stock valued at $195,446,000 after acquiring an additional 12,035 shares during the period. Bank of America Corp DE raised its holdings in Charles River Laboratories International by 13.4% in the 3rd quarter. Bank of America Corp DE now owns 1,163,348 shares of the medical research company’s stock worth $182,017,000 after purchasing an additional 137,335 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its holdings in Charles River Laboratories International by 33.0% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 769,437 shares of the medical research company’s stock worth $120,386,000 after purchasing an additional 190,828 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.